|
Correlation between multiorgan immune-related adverse events and clinical outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC) treated with chemo-immunotherapy. |
| |
|
No Relationships to Disclose |
| |
Martin Igor Gomez-Randulfe Rodriguez |
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
Mariantonietta Di Salvatore |
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; Celgene; Dompé Farmaceutici; Merck Serono; MSD Oncology |
Travel, Accommodations, Expenses - Merck Serono; MSD Oncology; Roche |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Pfizer; Roche |
Research Funding - AstraZeneca (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Roche |